

Research Article

Leukocyte telomere length is associated with iron overload in male adults with hereditary hemochromatosis

 Maximilino Martín¹, Andrea Millan², Florencia Ferraro¹,  Walter F. Tetzlaff¹, Ezequiel Lozano Chiappe¹, Eliana Botta¹, Marcelo Castro^{1,3}, Laura Boero¹, Jorge Rey^{1,3}, Jorge Daruich^{1,3}, Gustavo Frechtel², Tomas Meroño¹, Gloria Cerrone^{2,*} and Fernando Brites^{1,*}

¹Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina; ²Laboratorio de Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina; ³Hospital de clínicas 'José de San Martín', Departamento de Hemoterapia e Inmunohematología, División de Transfusión y Transmisión de Enfermedades, Universidad de Buenos Aires, Buenos Aires, Argentina

Correspondence: M. Martín (maxie.martin@hotmail.com)



Background: Hereditary hemochromatosis (HH) is a primary iron overload (IO) condition. Absolute telomere length (ATL) is a marker of cellular aging and DNA damage associated with chronic diseases and mortality.

Aim: To evaluate the relationship between ATL and IO in patients with HH.

Methods: Cross-sectional study including 25 patients with HH: 8 with IO and 17 without IO (ferritin < 300 ng/ml) and 25 healthy controls. Inclusion criteria were: age > 18 years, male sex and HH diagnosis. Patients with diabetes or other endocrine and autoimmune diseases were excluded. ATL was measured by real-time PCR.

Results: HH patients with IO were older ($P < 0.001$) and showed higher ferritin concentration ($P < 0.001$). Patients with HH, disregarding the iron status, showed higher glucose and body mass index (BMI) than controls (both $P < 0.01$). ATL was shorter in patients with IO than controls [with IO: 8 (6–14), without IO: 13 (9–20), and controls: 19 (15–25) kilobase pairs, $P < 0.01$]; with a linear trend within groups (P for trend < 0.01). Differences in ATL remained statistically significant after adjusting by age, BMI and glucose ($P < 0.05$).

Discussion: Patients with IO featured shorter ATL while patients without IO showed only mild alterations vs. controls. Screening for IO is encouraged to prevent iron-associated cellular damage and early telomere attrition.

Introduction

Hereditary hemochromatosis (HH) is a primary condition, which might lead to iron overload (IO) depending on host and ambient factors. Two main types of HH have been described: (1) the recessive type which involves genes that are related to the activation of hepcidin such as the human homeostatic iron regulator (*HFE*), hemojuvelin (*HJV*), and hepcidin (*HAMP*) genes; and (2) the dominant type which involves the hepcidin receptor ferroportin (*FPN*). Among these, the main gene associated with HH is *HFE*, located in the short arm of chromosome 6 (6p). The *HFE* gene encodes a protein that is located on the surface of cells, primarily liver, intestinal and immune cells. This protein interacts with other proteins on the cell surface to detect the amount of iron in the body. When the *HFE* protein is bound to the transferrin (Tf) receptor (TfR) 1, the receptor cannot bind to Tf preventing the entrance of iron to liver cells. Furthermore, *HFE* protein regulates the production of hepcidin. Hepcidin is produced by the liver, and it regulates iron absorption from the diet and its release from storage sites in the body. When the *HFE* protein is not bound

*These authors contributed equally to this work.

Received: 29 May 2020

Revised: 12 August 2020

Accepted: 11 September 2020

Accepted Manuscript online:
07 October 2020

Version of Record published:
23 October 2020

to TfR 1, it binds to a group of other proteins that include hepcidin triggering the production of hepcidin. Therefore, binding of HFE protein to TfR 1 represses hepcidin expression. Consequently, current models of iron metabolism regulation propose that highly iron-saturated Tf would release HFE protein from TfR1 increasing iron uptake by cells and hepcidin up-regulation [1,2].

Even if iron is essential for cells, it may also be involved in the generation of reactive oxygen species leading to cellular damage [3–7]. In patients with IO, the hepatocytes, cardiomyocytes and cells from endocrine organs, may be affected [8]. Clinical manifestations of overt IO in patients with HH include altered liver enzymes, hepatocellular carcinoma, osteoarthritis, glucose intolerance and diabetes, sexual hormone disorder, cardiac dysfunction and hyperpigmentation, among others [8]. In fact, IO would decrease insulin secretion and increase β -cell apoptosis via iron-induced oxidative stress [9]. Likewise, oxidative stress would be responsible for the liver damage found in IO patients [10,11]. Moreover, IO would be associated with increased atherosclerotic plaque formation and risk of myocardial infarction [12,13]. On the contrary, iron depletion, the most common and effective treatment for IO patients, would decrease low-density lipoprotein (LDL) oxidation and increase high-density lipoprotein cholesterol (HDL-C) levels [13]. Consistently, prior studies carried out by our group showed that HDL from IO patients present both quantitative and qualitative alterations associated with higher risk of cardiovascular disease [14,15].

Absolute telomere length (ATL) is related to aging and cellular damage. As a biomarker, it has been associated with insulin resistance, diabetes and cardiovascular diseases [16,17]. Telomeres are complex DNA–protein structures located at the end of eukaryotic chromosomes which shorten with age in all replicating somatic cells [18] and are associated with different pathological conditions [16,19]. In fact, functional telomeres play a key role in the protection of chromosomes against genome instability [20]. Given that iron might promote oxidative stress [21], which could also be a cause of shorter ATL [22], some studies evaluated the association between ATL and markers of iron metabolism. In fact, in a study of 1174 healthy adults, Tf saturation (TfSat), was associated with shorter ATL [23].

The present study aims to evaluate the relationship between iron levels and ATL in male adults diagnosed with HH.

Materials and methods

Subjects and study protocol

Thirty-eight patients with either TfSat > 50% or ferritin concentration > 300 ng/ml were recruited from the Hepatology Division of the University Hospital ‘José de San Martín’ between 2010 and 2012. HH was diagnosed by liver histology compatible with primary IO (iron deposition preferentially within hepatocytes in the periportal region of the hepatic lobule). Among the 38 patients recruited, 13 did not present liver histology compatible with IO and were excluded from the study. Additional inclusion criteria were adult age and male sex. Exclusion criteria were: diabetes, hypothyroidism, cirrhosis, viral hepatitis, HIV infection or cancer. Among the 25 patients with HH included, 8 showed overt IO (TfSat > 50% and ferritin concentration > 300 ng/ml) at the time of the analysis (HH with IO) and the remaining 17 presented TfSat > 50% but ferritin concentration < 300 ng/ml (HH w/o IO). These 17 patients had previously presented IO and had been submitted to a successful phlebotomy to decrease body iron levels. Eight patients were homozygous for the C282Y polymorphism, two were heterozygous for C282Y, one was homozygous for H63D, seven were heterozygous for H63D, one was a compound heterozygote for C282Y/H63D and six were wildtype. Twenty-five age-matched male healthy subjects without clinical or biochemical signs of IO and wildtype for mutations in the *HFE* gene were also included. A single blood sample from each subject was drawn from the antecubital vein after a 12-h overnight fast. Whole blood was used to determine the complete blood count and an aliquot was stored at -20°C to perform the ATL tests. Serum samples were immediately employed for general biochemical determinations.

The present study was carried out in accordance with the Declaration of Helsinki and its later amendments or comparable ethical standards. The protocol was approved by the Ethical Committees from University Hospital ‘José de San Martín’ and from the School of Pharmacy and Biochemistry, University of Buenos Aires. All patients signed an informed consent to participate in the study.

Anthropometric, analytical and genetic procedures

Height and weight were measured with the subject wearing light clothes and without shoes. Body mass index (BMI) was calculated and BMI categories were defined according to the World Health Organization (WHO) adult definition [24]. Complete blood count was carried out in a LH750 autoanalyzer (Beckman Coulter, Fullerton, CA, U.S.A.). Plasma Tf, apolipoprotein (apo) A-I and apo B concentrations were measured by nephelometry (IMMAGE[®], Beckman Coulter, Fullerton, CA, U.S.A.). Ferritin concentration was assayed by an electrochemiluminescence assay (VITROS[®] ECiQ, Ortho-Clinical Diagnostics, Raritan City, NJ, U.S.A.). Serum levels of iron, glucose, triglycerides

Table 1 Clinical and metabolic characteristics from IO patients and control subjects

Parameter	HH with IO (n=8)	HH w/o IO (n=17)	Controls (n=25)
Age (y)*	61 (55–67) ¹	44 (34–55) ²	49 (35–57) ²
BMI (kg/m ²)*	28 ± 3 ¹	28 ± 2 ¹	24 ± 2 ²
Glucose (mg/dl)*	102 (95–114) ¹	95 (90–113) ¹	89 (86–95) ²
TG (mg/dl)	96 (80–133)	113 (77–158)	86 (65–114)
TC (mg/dl)	167 ± 32	178 ± 38	186 ± 30
LDL-C (mg/dl)	99 ± 20	112 ± 35	119 ± 28
HDL-C (mg/dl)	50 ± 13	44 ± 8	48 ± 11
Apo A-I (mg/dl)	135 ± 30	127 ± 13	138 ± 31
Apo B (mg/dl)	84 ± 20	80 ± 32	94 ± 19
AST (IU/l)*	48 (32–57) ¹	32 (22–45) ²	19 (18–26) ²
ALT (IU/l)*	52 (28–72) ¹	28 (21–34) ²	20 (17–23) ²
Albumin (g/dl)	4.3 ± 0.3	4.4 ± 0.3	4.3 ± 0.1
Hepcidin/ferritin ratio*	0.03 ± 0.02 ¹	0.22 ± 0.21 ²	0.23 ± 0.17 ²
Tf (mg/dl)*	203 ± 38 ¹	248 ± 30 ²	249 ± 33 ²

Abbreviations: TC, total cholesterol; TG, triglyceride.

* = $P < 0.01$. Different superscript numbers over the mean or the median indicate significantly dissimilar groups.

and total cholesterol as well as the activities of hepatic enzymes were quantified by standardized methods (Roche Diagnostics, Mannheim, Germany) in a COBAS C501 autoanalyzer (Roche Diagnostics, Mannheim, Germany). LDL-C and HDL-C concentrations were determined by selective precipitation methods.

Measurement of ATL

The ATL measurement was carried out by qPCR as previously described [25], in a StepOne™ Real-Time PCR System (Applied Biosystems). Genomic DNA was extracted from peripheral blood leukocytes by standard protocols [26]. For each DNA sample, two consecutive reactions were performed: the first one to amplify a fragment of 75 bp of the single copy gene RPLPO (ribosomal protein, large, PO), and the second one for the telomeric sequence. They both were used for standard curve constructions, and allowed the genome/reaction number (S) and the of telomeric sequence/reaction (T) values to be exported from the respective standard curve. The calculation of the T/S ratio resulted in the kbp of telomeric sequence per cell for each individual determination.

Statistical analyses

The Shapiro–Wilks method was employed to assess data distribution. Normally distributed variables were expressed as mean ± SD and skewed-distributed variables as median (interquartile range [IQR]). Differences were analyzed by ANOVA employing Tukey's *post-hoc* test; or by Kruskal–Wallis and paired comparison *post-hoc* test according to normal or skewed data distribution, respectively. Significance was defined as $P < 0.05$ in the two-tailed tests. For all statistical analyses, the software INFostat (GrupoInfostat, Universidad Nacional de Córdoba, Argentina) was employed.

Results

Clinical and metabolic characteristics

HH patients with overt IO were older ($P < 0.001$) and, therefore, statistical analysis was carried out adjusting by age. Furthermore, HH patients with IO also showed higher AST and ALT activities, as well as ferritin concentration than HH patients without IO or control subjects ($P < 0.001$) (Table 1). In turn, all these parameters were similar in HH patients without IO and controls. Patients with HH, disregarding the iron status, showed higher BMI and glucose levels than the controls (both $P < 0.01$). Finally, TfSat was significantly different in the three groups studied finding the highest values in HH patients with IO and the lowest ones in control subjects (Figure 1). Lipid and lipoprotein profile were similar in all the groups.

Iron metabolism parameters

HH patient with IO showed higher levels of ferritin, TfSat (%), and body iron plus lower Tf compared with both HH patients without IO and controls. Additionally, HH patients without IO presented higher TfSat (%) and body




Figure 1. Iron metabolism in IO patients and control subjects

Panel A: Ferritin; Panel B: Transferrin Saturation (Transf. Sat.); Panel C: Body Iron; Panel D: Hepcidin. Different letters (a–c) indicate statistically significant differences.

iron than control subjects. There were no differences among the groups in hepcidin concentration (Figure 1), but hepcidin/ferritin ratio was significantly lower in HH patients with IO (Table 1).

ATL in patients with HH

A linear trend between the groups (P for trend < 0.01) was observed. ATL were shorter in patients with overt IO than in controls (Figure 2). Differences in ATL remained statistically significant in a model adjusted by age, BMI and glucose levels ($P < 0.05$).

ATL was significantly correlated with BMI ($r = -0.37$; $P < 0.05$), glucose ($r = -0.26$; $P < 0.01$), AST ($r = -0.36$; $P < 0.05$), ALT ($r = -0.35$, $P < 0.05$), TfSat ($r = -0.26$; $P < 0.05$), ferritin ($r = -0.38$; $P < 0.01$), and hepcidin ($r = -0.28$; $P < 0.05$). Moreover, no association was detected between HFE genotype/allele distribution and ATL. In multivariate analysis, glucose levels remained the only significant predictor of ATL ($r^2 = 0.32$; $\beta = -0.51$; $P < 0.01$) in a model that also included age, BMI and ferritin.

Discussion

Telomere shortening can impact tissue homeostasis by impairing cell proliferation and giving rise to genome instability, thus constituting the bases for the development of different pathological conditions [27]. The present study shows that HH patients with overt IO featured significantly shorter ATL while HH patients without IO showed only mild alterations in comparison with healthy controls. The exposition to elevated iron levels over time might be an important factor leading to telomere attrition in HH. The present results highlight the importance of early diagnosis and treatment of IO to preserve ATL.




Figure 2. Leukocyte telomere length in healthy controls and IO patients

Different letters (a-b) indicate statistically significant differences. * $P < 0.01$.

Excess iron deposition has been shown to be associated with oxidative damage of both circulating biomolecules and cells in a process that accelerates the physiologic changes that naturally occur with aging and leads, among others, to age-related conditions [3–7]. In fact, excess iron accumulation displays multiple toxic effects, which are mostly based on its ability to catalyze the generation of free radicals, resulting in cell death and tissue injury [21]. ROS generation is responsible for the onset of different cellular stress responses such as DNA damage, organelle fragmentation and membrane blebbing. Apart from being directly cytotoxic, iron and free radicals activate inflammatory cells, increasing cytokine production and further generation of ROS [28]. Evidence suggests that free radicals may damage telomere DNA and enhance its shortening [22]. Hence, ATL has been proposed as a marker of cumulative oxidative stress and biological aging [18,22,29].

Apart from the differences observed in the present study in telomere length among the three studied groups, the process of shortening seemed to be associated with the presence of IO. This finding is in agreement with a previous report [30] which showed that iron phenotype and not HFE genotype had a significant effect on telomere length. Patients with IO and, consequently, with the highest values of TfSat and ferritin, showed the shortest telomeres. Furthermore, our study indicates a significant inverse association between TfSat and ferritin levels with telomere length. Similar findings have also been previously reported by Mainou et al. [31], they observed that individuals with high TfSat presented shortened telomere length when compared with those with low TfSat. However, it is important to note that the present study did not include healthy controls and TfSat was the only parameter associated with iron metabolism analyzed in the study. Regarding ferritin levels, Liu et al. [32] observed that telomere length was negatively associated with the presence of high ferritin levels. Nevertheless, in the present study the association between ferritin and ATL was only significant for individuals over 65 years old. Notably, in the present study, ATL was negatively associated with markers of liver damage AST and ALT. This is interesting because the liver is one of the main targets of free radical-induced damage in IO patients [21]. Moreover, in the present study, ATL was inversely correlated with

BMI. This finding is consistent with several prior studies carried out by our group which showed increases in BMI and the presence of obesity as major determinants of telomere shortening [33,34].

In addition to oxidative stress, another trait of HH that would contribute to telomere shortening, is inflammation [35,36]. IO promotes liver inflammation which, in tandem with oxidative stress, could contribute to telomere attrition. In particular, iron deposits could directly alter the phenotype of T cells present in the liver leading to changes in cytokine expression [37]. In this regard, it is noteworthy that, as previously mentioned, ATL was negatively associated with ALT and AST levels. Both ALT and AST are considered markers of liver inflammation [38] and would suggest a link between the later and telomere shortening in IO patients.

Remarkably, in the multivariate analysis, glucose levels were the only independent predictor of ATL. This is an interesting finding because it raises the possibility that telomere shortening in IO patients could be the result of alterations in carbohydrate metabolism commonly observed in these patients. Telomere shortening is known to be a feature of diseases that primarily result from alterations in glucose homeostasis such as insulin resistance and diabetes [17]. Nevertheless, to our knowledge, this would be the first study to suggest that impairment in carbohydrate metabolism could be the main factor responsible for telomere shortening in pathologies with high glucose as a secondary trait as is the case with IO. Thus, on these bases, patients with chronic conditions that are frequently associated with hyperglycemia would be also prone to undergo a process of telomere shortening.

As far as we know, our study is the first to show that IO patients who underwent successful treatment aimed to reduce body iron levels and, therefore, systemic oxidative stress [39,40], present ATL values statistically similar to those of healthy controls. This is consistent with previous findings, both *in vivo* and *in vitro*, that indicate a positive effect of antioxidant therapy on telomere length [41,42]. Previous studies showed that the addition of N-acetylcysteine to both human lymphocytes exposed to irradiation and human astrocytoma cells infected with the human immunodeficiency virus decreases the rate of telomere attrition [43,44]. Similarly, serum drawn from subjects under a low-saturated fat diet showed the slowest rate of telomere shortening when added to the culture medium of human umbilical vein endothelial cells [45]. Furthermore, several studies reported an increase in telomere length after antioxidant supplementation in animal models [46,47]. Moreover, different double-blind, randomized placebo-controlled studies suggested that supplementation with ω -3 fatty acids could slow telomere attrition in both overweight patients and older-age individuals [48,49]. Similarly, Zhu et al. [50] observed a significant decrease in telomere attrition in overweight individuals after 4 months of vitamin D supplementation.

The fact that iron depletion could decrease telomere attrition is noteworthy given that the latter has been associated with shorter lifespan as well as a wide variety of age-related diseases and conditions, including cardiovascular disease, diabetes, insulin resistance and hypertension [30,51–54]. Regarding cardiovascular disease, telomere length has been proposed as a predictor of coronary heart disease events [55,56] and cardiovascular disease-related mortality [57,58]. In fact, telomere length would be associated with subclinical atherosclerosis markers such as carotid artery intima media thickness [59,60] and carotid artery calcification [51,61].

In summary, we observed an association between ATL and IO overt condition. HH patients with overt IO featured significantly shorter ATL, while HH patients without IO showed similar ATL when compared with healthy controls.

Conclusion

In conclusion, overt IO was associated with shorter ATL in patients with HH. Screening for IO is encouraged to prevent iron-associated cellular damage and early telomere attrition. ATL could provide prognostic information for IO-related complications in patients with HH.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the University of Buenos Aires [grant number UBACyT CB23]; the CONICET [grant number PIP 516]; and the ANPCyT [grant number PICT 2016-2018].

Author Contribution

Maximilino Martin carried out most of the biochemical assays detailed in the paper and contributed to the writing of the manuscript. Andrea Millan, Florencia Ferraro, Walter Tetzlaff, Ezequiel Lozano Chiappe, Eliana Botta and Marcelo Castro carried out the remaining part of the biochemical assays detailed in the paper. Laura Boero, Jorge Rey, Jorge Daruich, Gustavo Frechtel, Tomas Meroño, Gloria Cerrone and Fernando Brites contributed to the writing of the manuscript.

Abbreviations

ALT, alanine aminotransferase; Apo, apolipoprotein; AST, aspartate aminotransferase; ATL, absolute telomere length; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HFE, homeostatic iron regulator; HH, hereditary hemochromatosis; IO, iron overload; LDL, low-density lipoprotein; Tf, transferrin; TfR, Tf receptor; TfSat, Tf saturation.

References

- 1 Pantopoulos, K. (2008) Function of the hemochromatosis protein HFE: lessons from animal models. *World J. Gastroenterol.* **14**, 6893–6901
- 2 Katsarou, M., Papanavva, M., Latsi, R. and Drakoulis, N. (2019) Hemochromatosis: hereditary hemochromatosis and HFE gene. *Vitam. Horm.* **110**, 201–222
- 3 Pra, D., Franke, S.I.R., Henriques, J.A.P. and Fenech, M. (2012) Iron and genome stability: an update. *Mutat. Res.* **733**, 92–99
- 4 Xu, J., Marzetti, E., Seo, A.Y., Kim, J.S., Prolla, T.A. and Leeuwenburgh, C. (2010) The emerging role of iron dyshomeostasis in the mitochondrial decay of aging. *Mech. Ageing Dev.* **131**, 487–493, <https://doi.org/10.1016/j.mad.2010.04.007>
- 5 Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M. et al. (2008) Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. *J. Neurochem.* **106**, 1866–1875
- 6 Dunaief, J. (2006) Iron induced oxidative damage as a potential factor in age-related macular degeneration: The Cogan Lecture. *Invest. Ophthalmol. Vis. Sci.* **47**, 4660–4664, <https://doi.org/10.1167/iovs.06-0568>
- 7 Quintana, C., Bellefqih, S., Laval, J.Y., Guerin-Kern, J.L., Wu, T.D., Avila, J. et al. (2006) Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. *J. Struct. Biol.* **153**, 42–54, <https://doi.org/10.1016/j.jsb.2005.11.001>
- 8 Siddique, A. and Kowdley, K.V. (2012) Review article: the iron overload syndromes. *Aliment. Pharmacol. Ther.* **35**, 876–893, <https://doi.org/10.1111/j.1365-2036.2012.05051.x>
- 9 Simcox, J. and McClain, D.A. (2013) Iron and diabetes risk. *Cell Metab.* **17**, 329–341, <https://doi.org/10.1016/j.cmet.2013.02.007>
- 10 Datz, C., Muller, E. and Aigner, E. (2017) Iron overload and non-alcoholic fatty liver disease. 2017. *Miner. Endocrinol.* **42**, 173–183
- 11 Huan, H., Yang, Q., Zeyu, Z., Zelong, W., Dan, L., Zhangping, L. et al. (2018) Dual action of vitamin C in iron supplement therapeutics for iron deficiency anemia: prevention of liver damage induced by iron overload. *Food Funct.* **9**, 5390
- 12 Corti, M., Gaziano, M. and Hennekens, C.H. (1997) Iron status and risk of cardiovascular disease. *Ann. Epidemiol.* **7**, 62–68, [https://doi.org/10.1016/S1047-2797\(96\)00112-3](https://doi.org/10.1016/S1047-2797(96)00112-3)
- 13 Sullivan, J. (1999) Iron therapy and cardiovascular disease. *Kidney Int. Suppl.* **69**, 135–137, <https://doi.org/10.1046/j.1523-1755.1999.055Suppl.69135.x>
- 14 Meroño, T., Gómez Rosso, L., Sorroche, P., Boero, L., Arbelbide, J. and Brites, F. (2011) High risk of cardiovascular disease in iron overload patients. *Eur. J. Clin. Invest.* **41**, 479–486, <https://doi.org/10.1111/j.1365-2362.2010.02429.x>
- 15 Meroño, T., Brites, F., Dauteuille, C., Lhomme, M., Menafra, M., Arteaga, A. et al. (2015) Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload. *Clin. Sci. (Lond.)* **128**, 609–618, <https://doi.org/10.1042/CS20140300>
- 16 Haycock, P.C., Heydon, E.E., Kaptoge, S., Butterworth, A.S., Thompson, A. and Willeit, P. (2014) Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ* **349**, g4227, <https://doi.org/10.1136/bmj.g4227>
- 17 Verhulst, S., Dalgård, C., Labat, C., Kark, J.D., Kimura, M., Christensen, K. et al. (2016) A short leucocyte telomere length is associated with development of insulin resistance. *Diabetologia* **59**, 1258–1265, <https://doi.org/10.1007/s00125-016-3915-6>
- 18 Babizhayev, M.A., Savel'yeva, E.L., Moskvina, S.N. and Yegorov, Y.E. (2011) Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. *Am. J. Ther.* **18**, 209–226, <https://doi.org/10.1097/MJT.0b013e3181cf8ebb>
- 19 Martínez, P. and Blasco, M.A. (2017) Telomere-driven diseases and telomere-targeting therapies. *J. Cell Biol.* **216**, 875–887, <https://doi.org/10.1083/jcb.201610111>
- 20 O'Sullivan, R.J. and Karlseder, J. (2010) Telomeres: protecting chromosomes against genome instability. *Nat. Rev. Mol. Cell Biol.* **11**, 171–181, <https://doi.org/10.1038/nrm2848>
- 21 Bacon, B.R. and Britton, R.S. (1989) Hepatic injury in chronic iron overload. Role of lipid peroxidation. *Chem. Biol. Interact.* **70**, 183–226, [https://doi.org/10.1016/0009-2797\(89\)90045-8](https://doi.org/10.1016/0009-2797(89)90045-8)
- 22 von Zglinicki, T. (2000) Role of oxidative stress in telomere length regulation and replicative senescence. *Ann. N.Y. Acad. Sci.* **908**, 99–110, <https://doi.org/10.1111/j.1749-6632.2000.tb06639.x>
- 23 Shin, C. and Baik, I. (2017) Transferrin saturation concentrations associated with telomeric ageing: a population-based study. *Br. J. Nutr.* **117**, 1693–1701, <https://doi.org/10.1017/S0007114517001696>
- 24 World Health Organization (2020), <https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight>
- 25 O'Callaghan, N. and Fenech, M. (2011) A quantitative pcr method for measuring absolute telomere length. *Biol. Proced. Online.* **13**, 3, <https://doi.org/10.1186/1480-9222-13-3>
- 26 Murray, M. and Thompson, W.F. (1980) Rapid isolation of high molecular 611 weight plant DNA. *Nucleic Acids Res.* **8**, 4321–4325, <https://doi.org/10.1093/nar/8.19.4321>
- 27 Henriques, C.M. and Ferreira, M.G. (2012) Consequences of telomere shortening during lifespan. *Curr. Opin. Cell Biol.* **24**, 804–808, <https://doi.org/10.1016/j.ceb.2012.09.007>
- 28 Nakamura, T., Naguro, I. and Ichijo, H. (2019) Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. *Biochim. Biophys. Acta Gen. Subj.* **1863**, 1398–1409, <https://doi.org/10.1016/j.bbagen.2019.06.010>

- 29 Shammass, M. (2011) Telomeres, lifestyle, cancer, and aging. *Curr. Opin. Clin. Nutr. Metab. Care* **14**, 28–34, <https://doi.org/10.1097/MCO.0b013e32834121b1>
- 30 Mainous, III, A.G., Wright, R.U., Hulihan, M.M., Twal, W.O., McLaren, C.E., Diaz, V.A. et al. (2013) Telomere length and elevated iron: the influence of phenotype and HFE genotype. *Am. J. Hematol.* **88**, 492–496, <https://doi.org/10.1002/ajh.23438>
- 31 Mainous, III, A.G., Wright, R.U., Hulihan, M.M., Twal, W.O., McLaren, C.E., Diaz, V.A. et al. (2014) Elevated transferrin saturation, health-related quality of life and telomere length. *Biometals* **27**, 135–141, <https://doi.org/10.1007/s10534-013-9693-4>
- 32 Liu, B., Sun, Y., Xu, G., Snetselaar, L.G., Ludewig, G., Wallace, R.B. et al. (2019) Association between body iron status and leukocyte telomere length, a biomarker of biological aging, in a nationally representative sample of US adults. *Acad. Nutr. Diet.* **119**, 617–625, <https://doi.org/10.1016/j.jand.2018.09.007>
- 33 Gielen, M., Hageman, G.J., Antoniou, E.E., Nordfjall, K., Mangino, M., Balasubramanyam, M. et al. (2018) Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies. *Am. J. Clin. Nutr.* **108**, 453–475, <https://doi.org/10.1093/ajcn/nqy107>
- 34 Iglesias Molli, A., Panero, J., Dos Santos, P.C., González, C.D., Vilarinho, J., Sereday, M. et al. (2017) Metabolically healthy obese women have longer telomere length than obese women with metabolic syndrome. *PLoS ONE* **12**, e0174945, <https://doi.org/10.1371/journal.pone.0174945>
- 35 Kordinas, V., Ioannidis, A. and Chatzipanagiotou, S. (2016) The telomere/telomerase system in chronic inflammatory diseases. Cause or effect? *Genes (Basel)* **3**, 7
- 36 Zhang, J., Rane, G., Dai, X., Shanmugam, M.K., Arfuso, F., Samy, R.P. et al. (2016) Ageing and the telomere connection: an intimate relationship with inflammation. *Ageing Res. Rev.* **25**, 55–69, <https://doi.org/10.1016/j.arr.2015.11.006>
- 37 Hübscher, S.G. (2003) Iron overload, inflammation and fibrosis in genetic haemochromatosis. *J. Hepatol.* **38**, 521–525, [https://doi.org/10.1016/S0168-8278\(03\)00078-3](https://doi.org/10.1016/S0168-8278(03)00078-3)
- 38 McGill, M. (2016) The past and present of serum aminotransferases and the future of liver injury biomarkers. *EXCLI J.* **15**, 817–828
- 39 Houglum, K., Ramm, G.A., Crawford, D.H., Witztum, J.L., Powell, L.W. and Chojkier, M. (1997) Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. *Hepatology* **26**, 605–610, <https://doi.org/10.1002/hep.510260311>
- 40 Kaito, M., Iwasa, M., Kobayashi, Y., Fujita, N., Tanaka, H., Gabazza, E.C. et al. (2006) Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C. *J. Gastroenterol.* **41**, 921–922, <https://doi.org/10.1007/s00535-006-1871-5>
- 41 Glade, M. and Meguid, M. (2015) Oxidative telomere attrition, nutritional antioxidants and biological aging. *Nutrition* **31**, 1447–1451, <https://doi.org/10.1016/j.nut.2015.05.018>
- 42 Reichert, S. and Stier, A. (2017) Does oxidative stress shorten telomeres in vivo? A review. *Biol Lett.* **13**, pii:20170463, <https://doi.org/10.1098/rsbl.2017.0463>
- 43 Pereboeva, L., Westin, E., Patel, T., Flaniken, I., Lamb, L., Klingelutz, A. et al. (2013) DNA damage responses and oxidative stress in dyskeratosiscongenita. *PLoS ONE* **8**, e76473, <https://doi.org/10.1371/journal.pone.0076473>
- 44 Pollicita, M., Muscoli, C., Scgura, A., Biasin, A., Granato, T., Masuelli, L. et al. (2009) Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line. *BMC Neurosci.* **10**, 51, <https://doi.org/10.1186/1471-2202-10-51>
- 45 Marin, C., Delgado-Lista, J., Ramirez, R., Carracedo, J., Caballero, J., Perez-Martinez, P. et al. (2012) Mediterranean diet reduces senescence-associated stress in endothelial cells. *Age (Dordr.)* **34**, 1309–1316, <https://doi.org/10.1007/s11357-011-9305-6>
- 46 Badás, E., Martínez, J., Rivero de Aguilar Cachafeiro, J., Miranda, F., Figuerola, J. and Merino, S. (2015) Ageing and reproduction: antioxidant supplementation alleviates telomere loss in wild birds. *J. Evol. Biol.* **28**, 896–905, <https://doi.org/10.1111/jeb.12615>
- 47 Tarry-Adkins, J., Blackmore, H.L., Martin-Gronert, M.S., Fernandez-Twinn, D.S., McConnell, J.M., Hargreaves, I.P. et al. (2013) Coenzyme Q10 prevents accelerated cardiac aging in a rat model of poor maternal nutrition and accelerated postnatal growth. *Mol. Metab.* **2**, 480–490, <https://doi.org/10.1016/j.molmet.2013.09.004>
- 48 Kiecolt-Glaser, J., Epel, E., Belury, M., Andridge, R., Lin, J., Glaser, R. et al. (2013) Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. *Brain Behav. Immun.* **28**, 16–24, <https://doi.org/10.1016/j.bbi.2012.09.004>
- 49 O'Callaghan, N., Parletta, N., Milte, C.M., Benassi-Evans, B., Fenech, M. and Howe, P.R. (2014) Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω -3 fatty acid supplementation: a randomized controlled pilot study. *Nutrition* **30**, 489–491, <https://doi.org/10.1016/j.nut.2013.09.013>
- 50 Zhu, H., Guo, D., Li, K., Pedersen-White, J., Stallmann-Jorgensen, I., Huang, Y. et al. (2012) Increased telomerase activity and vitamin D supplementation in overweight africanamericans. *Int. J. Obes. (Lond.)* **36**, 10, <https://doi.org/10.1038/ijo.2011.197>
- 51 Mainous, III, A.G., Codd, V., Diaz, V.A., Schoepf, U.J., Everett, C.J., Player, M.S. et al. (2010) Leukocyte telomere length and coronary artery calcification. *Atherosclerosis* **210**, 262–267, <https://doi.org/10.1016/j.atherosclerosis.2009.10.047>
- 52 Adaikalakoteswari, A., Balasubramanyam, M. and Mohan, V. (2005) Telomere shortening occurs in Asian Indian Type 2 diabetic patients. *Diabetes Med.* **22**, 1151–1156, <https://doi.org/10.1111/j.1464-5491.2005.01574.x>
- 53 Demissie, S., Levy, D., Benjamin, E.J., Cupples, L.A., Gardner, J.P., Herbert, A. et al. (2006) Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. *Ageing Cell* **5**, 325–330, <https://doi.org/10.1111/j.1474-9726.2006.00224.x>
- 54 Kark, J., Nassar, H., Shaham, D., Sinnreich, R., Goldberger, N., Aboudi, V. et al. (2013) Leukocyte telomere length and coronary artery calcification in Palestinians. *Atherosclerosis* **229**, 363–368, <https://doi.org/10.1016/j.atherosclerosis.2013.05.030>
- 55 Brouillette, S., Moore, J.S., McMahon, A.D., Thompson, J.R., Ford, I., Shepherd, J. et al. (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. *Lancet* **369**, 107–114, [https://doi.org/10.1016/S0140-6736\(07\)60071-3](https://doi.org/10.1016/S0140-6736(07)60071-3)
- 56 Fitzpatrick, A., Kronmal, R.A., Gardner, J.P., Psaty, B.M., Jenny, N.S., Tracy, R.P. et al. (2007) Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. *Am. J. Epidemiol.* **165**, 14–21, <https://doi.org/10.1093/aje/kwj346>

- 57 Fitzpatrick, A., Kronmal, R.A., Kimura, M., Gardner, J.P., Psaty, B.M., Jenny, N.S. et al. (2011) Leukocyte telomere length and mortality in the Cardiovascular Health Study. *J. Gerontol. A Biol. Sci. Med. Sci.* **66**, 421–429, <https://doi.org/10.1093/gerona/glq224>
- 58 Bakaysa, S., Mucci, L.A., Slagboom, P.E., Boomsma, D.I., McClearn, G.E., Johansson, B. et al. (2007) Telomere length predicts survival independent of genetic influences. *Aging Cell* **6**, 769–774, <https://doi.org/10.1111/j.1474-9726.2007.00340.x>
- 59 O'Donnell, C., Demissie, S., Kimura, M., Levy, D., Gardner, J.P., White, C. et al. (2008) Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. *Arterioscler Thromb. Vasc. Biol.* **28**, 1165–1171, <https://doi.org/10.1161/ATVBAHA.107.154849>
- 60 De Meyer, T., Rietzschel, E.R., De Buyzere, M.L., Langlois, M.R., De Bacquer, D., Segers, P. et al. (2009) Systemic telomere length and preclinical atherosclerosis: the Asklepios Study. *Eur. Heart J.* **30**, 3074–3081, <https://doi.org/10.1093/eurheartj/ehp324>
- 61 Kroenke, C., Pletcher, M.J., Lin, J., Blackburn, E., Adler, N., Matthews, K. et al. (2012) Telomerase, telomere length, and coronary artery calcium in black and white men in the CARDIA study. *Atherosclerosis* **220**, 506–512, <https://doi.org/10.1016/j.atherosclerosis.2011.10.041>